Pharma and Life Sciences Blog

JUNE 22, 2023

How a Global CPG Company Saved Procurement Costs With GEP as Partner Vijendra Thu, 06/22/2023 - 23:47 A Fortune 500 global fast-food company wanted to open new outlets and expand to new geographies and was looking to build a more flexible and efficient global procurement operating model that would allow it to do so.

52

52

Express Pharma

MAY 30, 2023

ValGenesis and Life Science Consulting have partnered to provide digital validation solutions to enhance compliance and quality across life sciences disciplines such as production, quality control and assurance, information technology, and research and development (R&D). journey. .

73

73

STAT

NOVEMBER 1, 2023

The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

Pharmaceutical Companies 334

Pharmaceutical Companies Pharmaceutical Companies 334

STAT

APRIL 9, 2024

  The new company will be led by Daphne Zohar, the founding CEO of the biotech startup foundry PureTech Health, which helped launch both Karuna and Seaport.  

Drug Development 315

Drug Development 315

STAT

APRIL 18, 2024

It’s joining with private equity to launch a $4 billion primary care company. Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday.

295

295

STAT

APRIL 15, 2024

Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome, supporting the company’s decision to acquire its development partner two years ago.

Communication 292

Communication 292

STAT

SEPTEMBER 21, 2023

Anesthesia Partners and its private equity owner, Welsh, Carson, Anderson & Stowe, alleging in federal court the two partners formed a monopoly in order to drive up prices and boost their profits. Normally, the FTC sues the company that it believes has violated antitrust law. The Federal Trade Commission has sued U.S.

Hospitals 363

Hospitals 363

STAT

JANUARY 8, 2024

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

Mayo Clinic 326

Mayo Clinic 326

STAT

JANUARY 7, 2024

Insitro, a South San Francisco firm, was founded in 2018 by Daphne Koller, who had previously been a Stanford professor, a 2004 MacArthur “genius” grant recipient, and the co-founder and co-CEO of the online course company Coursera. Rowe Price, Arch Venture Partners, and Casdin Capital.

Drug Development 363

Drug Development 363

STAT

MARCH 4, 2024

Over the last few years, virtual mental health company Talkspace has been on a relentless quest to conquer the insurance market. And, the ability to serve adults 65 and older could prove an important distinction in the eyes of investors and potential strategic partners in the health care industry.

323

323

STAT

FEBRUARY 13, 2024

The company, BioAge, raised money from more than a dozen investors. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound.

281

281

STAT

OCTOBER 17, 2023

Revenue cycle management company Waystar filed for an initial public offering Monday with the Securities and Exchange Commission. The company did not specify how many shares it plans to offer or what share price it is targeting. billion market cap.

Hospitals 259

Hospitals 259

STAT

MAY 8, 2024

… A young boy died in a trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy , STAT writes, citing a note that was posted online by Parent Project Muscular Dystrophy and confirmed by the company. The company said it was still working to understand what happened and the exact cause. Deaths

256

256

STAT

AUGUST 1, 2023

Over the past two weeks, United Musculoskeletal Partners, U.S. Anesthesia Partners, and U.S. Radiology Specialists each registered with Forbes Tate Partners, a lobbying shop founded by political insiders who used to work in President Bill Clinton’s administration. Forbes Tate also did not respond.

Hospitals 246

Hospitals 246

STAT

FEBRUARY 26, 2024

R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares. per share, or roughly $5.8

Hospitals 261

Hospitals 261

STAT

OCTOBER 19, 2023

But while company executives were raising that capital, multiple employees were questioning the validity of preclinical data for its lead drug candidate, an investigation by STAT and the Boston Globe revealed in June. Now, Laronde is merging with another Flagship company, Senda Biosciences, according to a statement released Thursday.

336

336

STAT

NOVEMBER 17, 2023

The Food and Drug Administration has approved a Medtronic device to lower blood pressure, the company announced Friday evening. “We partnered closely with leading experts in our clinical community who could help us in our journey to get this technology to the people who need it most.”

334

334

STAT

APRIL 25, 2024

Regeneron Pharmaceuticals and Mammoth Biosciences are  partnering  to develop new CRISPR-based gene therapies. A hospital takes a gene therapy’s approval into its own hands What happens if, as an academic, you develop a promising gene therapy, but no company is willing to take it to market?

Hospitals 274

Hospitals Drug Pricing 274

STAT

AUGUST 30, 2023

A month after conducting significant layoffs, Biofourmis is out a CEO: Kuldeep Singh Rajput, one of the company’s founders, has quietly stepped down from his role.  The Boston-based company was valued at $1.3 Continue to STAT+ to read the full story…

Hospitals 311

Hospitals 311

STAT

OCTOBER 16, 2023

— Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

290

290

STAT

MARCH 25, 2024

And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But the company’s stock price fell 32% over the past five years.

Vaccines 363

Vaccines 363

STAT

FEBRUARY 12, 2024

Anesthesia Partners, alleging the two parties conspired to create monopolies for anesthesia services. The agency asked the judge last month to ignore those companies’ pleas, calling their arguments “unavailing” in recent legal filings.

321

321

STAT

DECEMBER 8, 2023

The former McKinsey partner joined CRISPR Therapeutics in 2015 as its chief business officer. STAT spoke to Kulkarni about how the company reached this point, and where the field of CRISPR-based medicine is going. Samarth “Sam” Kulkarni has been there from almost the beginning. In 2017, he was elevated to CEO.

326

326

STAT

JANUARY 4, 2024

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. The company is targeting the surrounding chemicals that influence how genes act. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes.

352

352

Pharma Mirror

MARCH 2, 2022

The post Aedesius Health and its lead biopharma company, AO BIO partner with Indegene for a comprehensive commercialization engagement appeared first on Pharma Mirror Magazine. Indegene’s Co-Commercialization model enables Aedesius Health and AO BIO to achieve their mission to reset.

52

52

STAT

FEBRUARY 29, 2024

That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol. Kristina Burow has a well-trained eye. Neumora was one of the few biotechs to go public through an IPO last year.

253

253

PharmExec

SEPTEMBER 21, 2023

Celexor Bio expected to focus on ell depletion of pathologic cells in autoimmune and inflammatory disorders.

52

52

STAT

OCTOBER 8, 2023

General Catalyst — which has backed household names like Airbnb and Warby Parker well before they were successful companies — did not say how much they’d invest to acquire a health system. It’s the most overt attempt by a venture firm to directly shape how hospitals use technology to provide care.

Hospitals 329

Hospitals 329

STAT

SEPTEMBER 22, 2023

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

Chemotherapy 311

Chemotherapy 311

STAT

FEBRUARY 22, 2023

The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions. Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines.

Vaccines 267

Vaccines 267

STAT

SEPTEMBER 27, 2023

But the huge amount of money and large number of study subjects involved also show the challenges inherent in improving on the vaccines already manufactured by Moderna as well as by Pfizer and its partner BioNTech. “The thing that is super interesting about this is that this is the government innovating,” he said.

Vaccines 342

Vaccines 342

STAT

AUGUST 25, 2023

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year. The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

246

246

STAT

FEBRUARY 17, 2023

Pfizer and partner Valneva are scrapping data from roughly half of the participants in a Phase 3 trial of a Lyme disease vaccine candidate after uncovering quality issues with a third-party clinical trial operator. Continue to STAT+ to read the full story…

Vaccines 265

Vaccines 265

Pharmaceutical Commerce

AUGUST 3, 2023

The agreement provides Scripta patients with another option when purchasing medication.

Drug Pricing 88

Drug Pricing 88

Pharmaceutical Technology

SEPTEMBER 21, 2023

The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.

Biosimilars 59

Biosimilars 59

Outsourcing Pharma

APRIL 16, 2024

Bios Health Group, a leading strategic and investment partner for life science companies and investors, has officially introduced the Bios Innovation Circle.

97

97

STAT

JUNE 26, 2023

Biogen shareholders voted to add biotech executive Susan Langer, who is the romantic partner of departing director Alex Denner, to its board of directors on Monday, concluding a weeklong episode that led some investors to question the company’s leadership. Langer, 32, will join the eight-member board for a one-year term.

246

246